Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Genizon BioSciences

Request full access

Genizon Biosciences discovers genes and biomarkers in common diseases using genome-wide association studies

Montreal, CanadaFounded 1999Biotech & Life Sciences

About Genizon BioSciences

Founded in 1999 and formerly known as Galileo Genomics, Genizon BioSciences was a Montreal-based genomics company that focused on discovering genes and biomarkers related to common diseases. The company's core strategy revolved around leveraging the unique genetic makeup of the Quebec founder population—a group descended from French immigrants who settled in the early 1600s—for its genome-wide association studies (GWAS). This particular population provided a relatively homogenous gene pool, which the company utilized to identify genetic susceptibilities for a range of complex disorders.

Genizon's business model was centered on forming partnerships with pharmaceutical companies to translate its genetic discoveries into new drug targets and diagnostic tools. The company successfully secured deals with major players like Pfizer, for Alzheimer's disease and attention-deficit disorder research, and Genentech, for Crohn's disease. Over its lifespan, Genizon raised a total of $130 million in funding over several rounds, with its final Series E round in 2008 bringing in $30.8 million. This capital was used to finance its extensive genome-wide association studies and to build comprehensive maps of genes and biomarkers for conditions such as schizophrenia, psoriasis, and metabolic syndrome.

Despite its initial promise and significant funding, Genizon BioSciences ceased operations and was placed into receivership in July 2011. The closure was primarily attributed to an inability to raise further funds as faster, more advanced technologies like next-generation sequencing surpassed Genizon's platform. The company's assets, including a substantial biobank of genetic material and advanced laboratory equipment, were subsequently handled by a court-appointed receiver.

Source: Dealroom company data

At a glance

Status
Closed
Open positions
None listed
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, DNA, Genetics and genomics, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B
Links
Website

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES EOther financing Jan 2008 $31M $123M BioFund Management · Investissement Desjardins · Biotech Turnaround Fund (BTF) —
SERIES DOther financing Feb 2007 $10M $40M Pfizer Ventures · Biotech Turnaround Fund (BTF) —
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Genizon BioSciences website traffic

Latest recorded traffic for Genizon BioSciences is 0 monthly website visits.

Latest monthly visits0
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Genizon BioSciences in the Montreal ecosystem

Live from Dealroom

The Genizon BioSciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Biofund
  • MMV Financial
  • Investissement Desjardins
  • Carnegie Asset Management

Series B and later5 investors entered at this stage

  • MVI
  • Biotech Turnaround Fund (BTF)
  • BioFund Management
  • Illumina
  • Pfizer Ventures

Other known investors1 additional known investor

  • HealthCap
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇦 Canada · Montreal HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Genizon BioSciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Genizon BioSciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.